Officials at the FDA say the injection is a more realistic option for groups where taking a daily pill was more of a challenge. Issues such as poverty, depression, other medical disorders and sometimes just plain forgetfulness, can make it hard to stick with medication on a daily basis.
A new injection to prevent HIV, rather than pills, is a game-changer, scientists say Read More »
News article announcing the U.S. Food and Drug Administration’s approval of Apretude
ViiV Healthcare, a subsidiary of GlaxoSmithKline (GSK), has secured the US Food and Drug Administration (FDA) approval for Apretude as a pre-exposure prophylaxis (PrEP) option to reduce the risk of acquiring HIV.
ViiV Healthcare gets FDA nod for Apretude to reduce risk of acquiring HIV Read More »
The Food and Drug Administration (FDA) has approved Apretude (cabotegravir extended-release injectable suspension) for use in at-risk adults and adolescents weighing at least 35kg for preexposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV infection.
FDA Approves Apretude, a Long-Acting Injectable for HIV PrEP Read More »
Since doctors treating HIV aren’t necessarily familiar with the workflow of giving injections, ViiV has run several studies to understand how to implement the process for administering an injectable. The company has spent most of the year partnering with clinics and healthcare delivery networks to straighten out that process, Waterhouse said.
AVAC commentary regarding the announcement of the U.S. Food and Drug Administration’s approval of Apretude
CAB-LA was superior to daily oral TDF–FTC in preventing HIV infection among MSM and transgender women. Strategies are needed to prevent INSTI resistance in cases of CAB-LA PrEP failure.
Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women Read More »
What should people who might consider taking injectable cabotegravir for PrEP know about the new research?
Cabotegravir for PrEP: Resistance, infections & more explained Read More »
